MetaCap

Biofrontera (BFRI) vs Radiopharm Theranostics (RADX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Biofrontera (BFRI) has outperformed Radiopharm Theranostics (RADX) over the past year, losing 28.4% versus a loss of 86.1%. Radiopharm Theranostics is the larger company by market cap ($9.9 million vs $9.5 million), about 1.0 times the size. Biofrontera converts more of its revenue into profit, with a net margin of -25.3% versus -1055.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BFRI-28.38%RADX-86.15%
+145%+24%-97%
Nov 21, 20251 yearNov 20, 2026
BFRI-47.00%RADX-96.66%
+69%-18%-105%
Dec 2, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BFRI versus RADX key metrics
MetricBFRIRADX
Share price$0.53$0.6304
Market cap$9.51M$9.90M
1-day change-7.02%-9.71%
YTD return-7.02%-87.92%
1-year return-28.38%-86.15%
5-year return-99.66%—
Forward P/E1.32—
EPS (TTM)$-0.26$-3.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$41.70M$3.63M
Revenue growth (YoY)+11.75%+1114.27%
Net income (latest FY)$-10.54M$-38.34M
Gross margin—1.08%
Operating margin-27.21%-1050.63%
Net margin-25.26%-1055.27%
52-week high$1.66$16.25
52-week low$0.53$0.63
Distance from 52-week high-68.07%-96.12%
Analyst consensusnonestrong_buy
Avg. price target upside+1032.08%+2595.11%
Average volume429.04K55.23K
Shares outstanding17.95M15.70M
Employees8414
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BFRI has outperformed RADX by 57.8 percentage points over the past year.
  • Biofrontera is more profitable, keeping -25.3 cents of every revenue dollar as net income versus -1055.3 cents for Radiopharm Theranostics.
  • Radiopharm Theranostics grew revenue faster in its latest fiscal year (+1114.27% vs +11.75%).

About Biofrontera

BFRI stock →

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions.

Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees

About Radiopharm Theranostics

RADX stock →

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

BFRI vs RADX FAQ

Which is bigger, Biofrontera or Radiopharm Theranostics?

Radiopharm Theranostics (RADX) is larger, with a market capitalization of $9.90M compared with $9.51M for Biofrontera (BFRI).

Which stock has performed better over the past year, BFRI or RADX?

BFRI returned -28.38% over the past 12 months, compared with -86.15% for RADX (price return, excluding dividends). Past performance does not predict future results.

Are Biofrontera and Radiopharm Theranostics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons